Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Nov 2:10:1005926.
doi: 10.3389/fcell.2022.1005926. eCollection 2022.

MSCs vs. iPSCs: Potential in therapeutic applications

Kalaiselvaan Thanaskody  1 , Amirah Syamimi Jusop  1 , Gee Jun Tye  2 , Wan Safwani Wan Kamarul Zaman  3   4 , Sylvia Annabel Dass  2 , Fazlina Nordin  1
Affiliations
Review

MSCs vs. iPSCs: Potential in therapeutic applications

Kalaiselvaan Thanaskody et al. Front Cell Dev Biol. .

Abstract

Over the past 2 decades, mesenchymal stem cells (MSCs) have attracted a lot of interest as a unique therapeutic approach for a variety of diseases. MSCs are capable of self-renewal and multilineage differentiation capacity, immunomodulatory, and anti-inflammatory properties allowing it to play a role in regenerative medicine. Furthermore, MSCs are low in tumorigenicity and immune privileged, which permits the use of allogeneic MSCs for therapies that eliminate the need to collect MSCs directly from patients. Induced pluripotent stem cells (iPSCs) can be generated from adult cells through gene reprogramming with ectopic expression of specific pluripotency factors. Advancement in iPS technology avoids the destruction of embryos to make pluripotent cells, making it free of ethical concerns. iPSCs can self-renew and develop into a plethora of specialized cells making it a useful resource for regenerative medicine as they may be created from any human source. MSCs have also been used to treat individuals infected with the SARS-CoV-2 virus. MSCs have undergone more clinical trials than iPSCs due to high tumorigenicity, which can trigger oncogenic transformation. In this review, we discussed the overview of mesenchymal stem cells and induced pluripotent stem cells. We briefly present therapeutic approaches and COVID-19-related diseases using MSCs and iPSCs.

Keywords: COVID-19; SARS-CoV-2; induced pluripotent stem cells; mesenchymal stem cells; therapeutic applications.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

FIGURE 1
FIGURE 1
Schematic representation of the differentiation-based stem cells based on differentiation. Created by Biorender.com.
FIGURE 2
FIGURE 2
Summary of mesenchymal stem cells and induced pluripotent stem cells. Created by Biorender.com.
FIGURE 3
FIGURE 3
Schematic diagram of MSC-based cell therapy. Created by Biorender.com.
FIGURE 4
FIGURE 4
Schematic diagram of iPSC-based cell therapy. Created by Biorender.com.
FIGURE 5
FIGURE 5
Different methods of integrating and non-integrating viral vectors are used in cell reprogramming to generate iPSCs. Created by Biorender.com.
FIGURE 6
FIGURE 6
Different methods involved in reprogramming using integrating and non-integrating non-viral vectors. Created by Biorender.com.
See this image and copyright information in PMC

References

    1. Aasen T., Raya A., Barrero M. J., Garreta E., Consiglio A., Gonzalez F., et al. (2008). Efficient and rapid generation of induced pluripotent stem cells from human keratinocytes. Nat. Biotechnol. 26 (11), 1276–1284. 10.1038/nbt.1503 - DOI - PubMed
    1. Ahmad Mulyadi Lai H. I., Chou S.-J., Chien Y., Tsai P.-H., Chien C.-S., Hsu C.-C., et al. (2021). Expression of endogenous angiotensin-converting enzyme 2 in human induced pluripotent stem cell-derived retinal organoids. Int. J. Mol. Sci. 22 (3), 1320. 10.3390/ijms22031320 - DOI - PMC - PubMed
    1. Akbari A., Rezaie J. (2020). Potential therapeutic application of mesenchymal stem cell-derived exosomes in SARS-CoV-2 pneumonia. Stem Cell Res. Ther. 11 (1), 356. 10.1186/s13287-020-01866-6 - DOI - PMC - PubMed
    1. Al Abbar A., Ngai S. C., Nograles N., Alhaji S. Y., Abdullah S. (2020). Induced pluripotent stem cells: Reprogramming platforms and applications in cell replacement therapy. Biores. Open Access 9 (1), 121–136. 10.1089/biores.2019.0046 - DOI - PMC - PubMed
    1. Al-Anazi K. A. (2020). “Introductory chapter,” in Update on mesenchymal and induced pluripotent stem cells. London: IntechOpen. 10.5772/intechopen.90236 - DOI